CDK7 is a novel therapeutic vulnerability in Fibrolamellar cancer
To identify targets in Fibrolamellar cancer (FLC), we introduced the FLC driver gene mutation (DNAJB1-PRKACA) into HepG2 cells to engineer FLC cell lines. We then performed gene expression profiling analysis using data obtained from RNA-seq of 6 different cell samples from HepG2, H33 (FLC cell line) and H12 (FLC cell line) Overall design: Comparative gene expression profiling analysis of RNA-seq data for HepG2 (control, n = 6) vs H33 (n = 6) and HepG2 (control, n = 6) vs H12 (n = 6)